The Age of Pharmabrewing

We should not resist developing opiate-producing GM yeast for fear of the technology falling into the wrong hands.

Written byLaura Marengo and John D. Loike
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

© LONELY/SHUTTERSTOCK

Genetically modified (GM) organisms have become an established part of the American landscape. GM plants, for example, are used in farming to produce more than 92 percent of all corn and 94 percent of all soy in the United States. Even in the pharmaceutical industry, innovative technologies involving GM yeast are being used to economically produce commercial drugs, such as hepatitis B and malaria vaccines, that are otherwise too costly. Yeast-based synthesis of hepatitis vaccines costs around $1 per dose, compared with $20–$40 per dose for standard hepatitis vaccines. GM yeast is now also being employed to produce ethically contentious drugs, such as cannabinoids and, most recently, opiates—a market estimated to be worth more than $8 billion.

Although yet to reach the market, such technology ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • The Scientist Placeholder Image
    This person does not yet have a bio.View Full Profile
  • John Loike

    John Loike serves as the interim director of bioethics at New York Medical College and as a professor of biology at Touro University. He served previously as the codirector for graduate studies in the Department of Physiology Cellular Biophysics and director of Special Programs in the Center for Bioethics at Columbia University College of Physicians and Surgeons. His biomedical research focuses on how human white blood cells combat infections and cancer. Loike lectures internationally on emerging topics in bioethics, organizes international conferences, and has published more than 150 papers and abstracts in the areas of immunology, cancer, and bioethics. He earned his Ph.D. from the Albert Einstein College of Medicine of Yeshiva University.

    View Full Profile

Published In

Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Explore new strategies for improving plasmid DNA manufacturing workflows.

Overcoming Obstacles in Plasmid DNA Manufacturing

cytiva logo
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies